Know Cancer

or
forgot password

A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (IND# 69896) in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma


Phase 2
2 Years
30 Years
Open (Enrolling)
Both
Childhood Hepatocellular Carcinoma, Papillary Thyroid Cancer, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Rhabdomyosarcoma, Recurrent Thyroid Cancer, Recurrent Wilms Tumor and Other Childhood Kidney Tumors

Thank you

Trial Information

A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (IND# 69896) in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma


PRIMARY OBJECTIVES:

I. To determine the objective response rate to sorafenib tosylate (sorafenib) in children
with relapsed or refractory rhabdomyosarcoma, Wilms tumor, hepatocellular carcinoma (HCC),
or papillary thyroid carcinoma (PTC).

SECONDARY OBJECTIVES:

I. To further define and describe the toxicities of sorafenib administered on an oral,
twice-daily continuous schedule.

II. To further characterize the pharmacokinetics of sorafenib in children with refractory
cancer.

III. To estimate the progression-free survival on sorafenib for rhabdomyosarcoma, Wilms
tumor, and hepatocellular carcinoma and compare to a group of patients enrolled on selected
closed Phase II studies of Children Oncology Group (COG).

IV. To assess the biologic activity of sorafenib on vascular endothelial growth factor
(VEGF) and soluble vascular endothelial growth factor receptor-2 (VEGFR-2) in peripheral
blood samples. (Exploratory) V. To evaluate the presence of BRAF mutations and RET/PTC
rearrangements in patients with PTC. (Exploratory)

OUTLINE: This is a multicenter study. Patients are stratified according to diagnosis
(rhabdomyosarcoma vs Wilms tumor vs hepatocellular carcinoma vs papillary thyroid
carcinoma).

Patients receive sorafenib tosylate orally (PO) twice daily (BID) on days 1-28. Treatment
repeats every 28 days for up to 24 courses in the absence of disease progression or
unacceptable toxicity.

Patients undergo blood sample collection at baseline and periodically during study for
pharmacokinetic studies, and VEGF and VEGFR-2 analysis by ELISA. Previously collected
formalin-fixed paraffin-embedded tissue samples, from patients with papillary thyroid
carcinoma, are also analyzed for BRAF mutation and RET/PTC rearrangements by PCR.

After completion of study treatment, patients are followed up for up to 5 years.


Inclusion Criteria:



- Patients must have had histologic verification of one of the malignancies listed
below at original diagnosis or at relapse:

- Rhabdomyosarcoma (RMS)

- Wilms tumor

- Hepatocellular carcinoma (HCC)

- Papillary thyroid carcinoma (PTC)

- Patients must have relapsed or refractory disease (RMS, Wilms tumor, HCC, PTC)

- Patients must have radiographically measurable disease; measurable disease is
defined as the presence of at least one lesion on magnetic resonance imaging
(MRI) or computed tomography (CT) scan that can be accurately measured with the
longest diameter a minimum of 10 mm in at least one dimension (CT scan slice
thickness no greater than 5 mm)

- The following do not qualify as measurable disease:

- Malignant fluid collections (e.g., ascites, pleural effusions)

- Bone marrow infiltration

- Lesions only detected by nuclear medicine studies (e.g., bone,
gallium, or positron emission tomography [PET] scans)

- Elevated tumor markers in plasma or cerebrospinal fluid(CSF)

- Previously radiated lesions that have not demonstrated clear
progression post radiation

- Leptomeningeal lesions that do not meet the requirements noted above

- Patients with HCC must be relapsed or refractory to conventional chemotherapy

- Patients with PTC must be refractory to radioactive iodine (RAI)

- Patient's current disease state must be one for which there is no known curative
therapy or therapy proven to prolong survival with an acceptable quality of life

- Patients with known metastasis to the brain will be excluded from trial participation
unless treated surgically or with radiotherapy and stable with no recurrent lesions
for at least 3 months

- Rhabdomyosarcoma and Wilms strata: patients must be ≥ 24 months and ≤ 30 years of age
at study enrollment

- Hepatocellular carcinoma (HCC): patients must be ≥ 24 months and < 18 years of age at
study enrollment

- Papillary thyroid carcinoma (PTC): patients must be ≥ 24 months and ≤ 21 years of age
at study enrollment

- Patients must have a Lansky or Karnofsky performance status score of ≥ 50%,
corresponding to ECOG categories 0, 1, or 2

- Use Karnofsky for patients > 16 years of age and Lansky for patients ≤ 16 years
of age

- Patients who are unable to walk because of paralysis, but who are up in a
wheelchair, will be considered ambulatory for the purpose of assessing the
performance score

- Peripheral absolute neutrophil count (ANC) ≥ 1,000/μL

- Platelet count ≥ 75,000/μL (transfusion independent, defined as not receiving
platelet transfusions within a 7-day period prior to enrollment)

- Hemoglobin 8.0 g/dL (may receive red blood cell[RBC] transfusions)

- Creatinine clearance or radioisotope glomerular filtration rate(GFR) 70 mL/min OR a
serum creatinine based on age/gender as follows:

- 0.8 mg/dL (2 to < 6 years of age)

- 1.0 mg/dL (6 to < 10 years of age)

- 1.2 mg/dL (10 to < 13 years of age)

- 1.5 mg/dL (male) or 1.4 mg/dL (female) (13 to < 16 years of age)

- 1.7 mg/dL (male) or 1.4 mg/dL (female) (≥ 16 years of age)

- Total bilirubin ≤ 1.5 times upper limit of normal (ULN) for age

- SGPT (ALT) ≤ 135 U/L (for the purpose of this study, the ULN for SGPT is 45 U/L)

- PT, PTT, and INR < 1.5 times ULN

- Normal serum lipase and amylase (per institutional normal values)

- No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94%
if there is clinical indication for determination

- A blood pressure (BP) ≤ the 95^th percentile for age, height, and gender; and not
receiving medication for treatment of hypertension

- Patients who are pregnant or breast-feeding are not eligible

- Negative pregnancy tests must be obtained in girls who are post-menarchal

- Males or females of reproductive potential may not participate unless they have
agreed to use an effective contraceptive method beginning at the signing of the
informed consent until at least 30 days after the last dose of the study drug

- Patients with clinical symptoms of hepatic encephalopathy or ascites are not eligible

- Patients who have an uncontrolled infection are not eligible

- Patients with evidence of bleeding diathesis are not eligible

- Patients with known Gilbert syndrome are not eligible

- Patients who, in the opinion of the investigator, may not be able to comply with the
safety-monitoring requirements of the study are not eligible

- No concurrent chemotherapy, radiation therapy, immunomodulating agents, or other
investigational agents

- Patients must have fully recovered from the acute toxic effects of all prior
chemotherapy, immunotherapy, or radiotherapy prior to entering this study

- Patients with solid tumors must not have received myelosuppressive chemotherapy
within 3 weeks of enrollment onto this study (6 weeks if prior nitrosourea)

- At least 7 days must have elapsed since the completion of therapy with a growth
factor (at least 14 days must have elapsed after receiving pegfilgrastim)

- At least 7 days must have elapsed since completion of therapy with a biologic agent;

- For agents that have known adverse events occurring beyond 7 days after
administration, this period prior to enrollment must be extended beyond the time
during which adverse events are known to occur

- At least 3 half-lives must have elapsed since prior therapy that included a
monoclonal antibody

- At least 2 weeks must have elapsed since local palliative radiotherapy (XRT) (small
port); ≥ 3 months must have elapsed if prior craniospinal XRT was received, if ≥ 50%
of the pelvis was irradiated, or if TBI was received; ≥ 6 weeks must have elapsed if
other substantial bone marrow irradiation was given

- No evidence of active graft-vs-host disease and ≥ 2 months must have elapsed since
transplant (stem cell transplant or rescue without total-body irradiation)

- For patients with papillary thyroid carcinoma (PTC) only: ≥ 3 weeks from prior
radioiodine (RAI) treatment

- Patients requiring corticosteroids that have not been on a stable or decreasing dose
of corticosteroid for 7 days prior to enrollment are not eligible

- Patients who are currently receiving another investigational drug are not eligible

- Patients who are currently receiving other anti-cancer agents are not eligible

- Patients who are receiving cyclosporine, tacrolimus or other agents to prevent either
graft-versus-host disease post bone marrow transplant or organ rejection post
transplant are not eligible for this trial

- Patients who take cytochrome P450 enzyme-inducing anti-epileptic drugs (phenytoin,
carbamazepine, or phenobarbital), rifampin, grapefruit juice, or St. Johns wort will
not be eligible for the trial

- Patients who have received prior treatment with sorafenib are not eligible

- Patients must not be on therapeutic anti-coagulation;

- Prophylactic anticoagulation (i.e., low-dose warfarin) of venous or arterial
devices is allowed provided that the requirements for prothrombin time(PT),
partial thromboplastin time(PTT), and international normalized ratio(INR) are
met

Type of Study:

Interventional

Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Objective response by RECIST criteria v 1.1

Outcome Description:

Response rates will be calculated as the percent of evaluable patients who are responders, and confidence intervals will be constructed according to the method of Chang

Outcome Time Frame:

Up to 5 years

Safety Issue:

No

Principal Investigator

AeRang Kim

Investigator Role:

Principal Investigator

Investigator Affiliation:

Children's Oncology Group

Authority:

United States: Food and Drug Administration

Study ID:

NCI-2012-00106

NCT ID:

NCT01502410

Start Date:

January 2012

Completion Date:

Related Keywords:

  • Childhood Hepatocellular Carcinoma
  • Papillary Thyroid Cancer
  • Previously Treated Childhood Rhabdomyosarcoma
  • Recurrent Childhood Liver Cancer
  • Recurrent Childhood Rhabdomyosarcoma
  • Recurrent Thyroid Cancer
  • Recurrent Wilms Tumor and Other Childhood Kidney Tumors
  • Carcinoma
  • Thyroid Neoplasms
  • Kidney Neoplasms
  • Liver Neoplasms
  • Wilms Tumor
  • Rhabdomyosarcoma
  • Thyroid Diseases
  • Rhabdomyosarcoma, Embryonal
  • Carcinoma, Hepatocellular

Name

Location

Baylor College of MedicineHouston, Texas  77030
Memorial Sloan Kettering Cancer CenterNew York, New York  10021
Roswell Park Cancer InstituteBuffalo, New York  14263
Mayo ClinicRochester, Minnesota  55905
Children's Hospital of PhiladelphiaPhiladelphia, Pennsylvania  19104
University of Mississippi Medical CenterJackson, Mississippi  39216-4505
Washington University School of MedicineSaint Louis, Missouri  63110
Medical City Dallas HospitalDallas, Texas  75230
Midwest Children's Cancer CenterMilwaukee, Wisconsin  53226
Sinai Hospital of BaltimoreBaltimore, Maryland  21225
Bronson Methodist HospitalKalamazoo, Michigan  49007
Vanderbilt-Ingram Cancer CenterNashville, Tennessee  37232-6838
Morristown Memorial HospitalMorristown, New Jersey  07962-1956
Dana-Farber Cancer InstituteBoston, Massachusetts  02115
University of Arkansas for Medical SciencesLittle Rock, Arkansas  72205
Hackensack University Medical CenterHackensack, New Jersey  07601
Children's Hospital Los AngelesLos Angeles, California  90027-0700
Children's National Medical CenterWashington, District of Columbia  20010-2970
All Children's HospitalSt. Petersburg, Florida  33701
Saint Jude Midwest AffiliatePeoria, Illinois  61637
Carolinas Medical CenterCharlotte, North Carolina  28232-2861
University of Oklahoma Health Sciences CenterOklahoma City, Oklahoma  73104
Driscoll Children's HospitalCorpus Christi, Texas  78466
Southern California Permanente Medical GroupDowney, California  90242
Children's Hospital Central CaliforniaMadera, California  93638-8762
Kosair Children's HospitalLouisville, Kentucky  40202-3830
Children's Hospital Medical Center of AkronAkron, Ohio  44308
Overlook HospitalSummit, New Jersey  07902-0220
Cincinnati Children's Hospital Medical CenterCincinnati, Ohio  45229-3039
Montefiore Medical CenterBronx, New York  10467-2490
Rady Children's Hospital - San DiegoSan Diego, California  92123-4282
University of New Mexico Cancer CenterAlbuquerque, New Mexico  87131-5636
Nationwide Children's HospitalColumbus, Ohio  43205-2696
Children's Hospital of Pittsburgh of UPMCPittsburgh, Pennsylvania  15213
Presbyterian HospitalCharlotte, North Carolina  28233-3549
Lee Memorial Health SystemFort Myers, Florida  33902
University of Alabama at BirminghamBirmingham, Alabama  35294-3300
Children's Hospital of AlabamaBirmingham, Alabama  35233
Connecticut Children's Medical CenterHartford, Connecticut  06106
University of North CarolinaChapel Hill, North Carolina  27599
Nemours Children's Clinic - PensacolaPensacola, Florida  32504
Wayne State UniversityDetroit, Michigan  48202
BI-LO Charities Children's Cancer CenterGreenville, South Carolina  29605
University of Texas Southwestern Medical CenterDallas, Texas  
University of KentuckyLexington, Kentucky  40536-0098
Oregon Health and Science UniversityPortland, Oregon  97201
Tulane University Health Sciences CenterNew Orleans, Louisiana  70112
Florida HospitalOrlando, Florida  32803
University of Chicago Comprehensive Cancer CenterChicago, Illinois  60637-1470
Seattle Children's HospitalSeattle, Washington  98105
Wake Forest University Health SciencesWinston-Salem, North Carolina  27157
Childrens Memorial HospitalChicago, Illinois  60614
University of HawaiiHonolulu, Hawaii  96813
Saint John's Mercy Medical CenterSaint Louis, Missouri  63141
Columbia University Medical CenterNew York, New York  10032
State University of New York Upstate Medical UniversitySyracuse, New York  13210
University of IllinoisChicago, Illinois  60612
Cook Children's Medical CenterFort Worth, Texas  76104
The Children's Medical Center of DaytonDayton, Ohio  45404
University of Minnesota Medical Center-FairviewMinneapolis, Minnesota  55455
Children's Oncology GroupArcadia, California  91006-3776
Southern Illinois UniversitySpringfield, Illinois  62702
Riley Hospital for ChildrenIndianapolis, Indiana  46202
UMDNJ - Robert Wood Johnson University HospitalNew Brunswick, New Jersey  08903
Miller Children's HospitalLong Beach, California  90806
Childrens Hospital of Orange CountyOrange, California  92868-3874
Alfred I duPont Hospital for ChildrenWilmington, Delaware  19803
Nemours Children's Clinic - JacksonvilleJacksonville, Florida  32207-8426
Nemours Childrens Clinic - OrlandoOrlando, Florida  32806
Saint Joseph Children's Hospital of TampaTampa, Florida  33607
Children's Healthcare of Atlanta - EglestonAtlanta, Georgia  30322
The Childrens Mercy HospitalKansas City, Missouri  64108
Rainbow Babies and Childrens HospitalCleveland, Ohio  44106
East Tennessee Childrens HospitalKnoxville, Tennessee  37916
Children's Hospital and Medical Center of OmahaOmaha, Nebraska  68114
Childrens Hospital-King's DaughtersNorfolk, Virginia  23507
Dana-Farber Harvard Cancer CenterBoston, Massachusetts  02115
Mark O Hatfield-Warren Grant Magnuson Clinical CenterBethesda, Maryland  20892
University of California San Francisco Medical Center-ParnassusSan Francisco, California  94143
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical CenterDenver, Colorado  80218
Greenville Cancer Treatment CenterGreenville, South Carolina  29605
Providence Sacred Heart Medical Center and Children's HospitalSpokane, Washington  99204